Earnings Call Summary | NeuroPace(NPCE.US) Q2 2024 Earnings Conference
Earnings Call Summary | NeuroPace(NPCE.US) Q2 2024 Earnings Conference
Operating expenses were tightly controlled, resulting in a net loss of $7.5 million for Q2 2024, an improvement from a net loss of $9.1 million in Q2 2023.The following is a summary of the NeuroPace, Inc. (NPCE) Q2 2024 Earnings Call Transcript:
以下是NeuroPace, Inc. (NPCE) 2024年第二季度業績會紀要：
Financial Performance:
金融業績：
NeuroPace reported a revenue of $19.3 million for Q2 2024, representing a 17% growth compared to the same period last year.
Gross margin for Q2 2024 was 73.4%, an improvement from 72.5% in Q2 2023, primarily due to increased RNS system sales.
Operating expenses were tightly controlled, resulting in a net loss of $7.5 million for Q2 2024, an improvement from a net loss of $9.1 million in Q2 2023.
NeuroPace報告2024年第二季度營業收入爲1930萬美元，同比去年同期增長了17%。
2024年第二季度毛利率爲73.4%，較2023年第二季度的72.5%有所提升，主要是由於RNS系統的銷售增加。
由於控制了營銷費用，2024年第二季度淨虧損爲750萬美元，較2023年第二季度的淨虧損910萬美元有所改善。
Business Progress:
業務進展：
NeuroPace continues to drive adoption and utilization of the RNS system in level four centers and is expanding access through the Project CARE program.
The company has completed training new sales representatives, who will support revenue growth, especially in territories outside level four centers.
The NAUTILUS study for expanding RNS system indications is progressing well, with all implants completed and the trial now in the patient follow-up phase.
NeuroPace繼續推動級別四中心對RNS系統的採用和利用，並通過Project CARE計劃擴大其覆蓋範圍。
該公司已經完成了新銷售代表的培訓，他們將支持營收增長，尤其是在級別四中心以外的地區。
NAUTILUS擴大RNS系統適應症的研究進展順利，所有的植入物都完成了，現在正在進行患者隨訪階段。
Opportunities:
機會：
Continued expansion of RNS system adoption and utilization offers significant market potential, given the $2 billion annual market opportunity for drug-resistant epilepsy patients within level four centers.
The Project CARE program pilot phase is showing positive early results in increasing patient referrals, which could lead to broader adoption of RNS therapy.
持續擴大RNS系統的採用和利用，將爲四級中心內藥物難治性癲癇患者提供20億美元的市場機會。
Project CARE計劃試點階段顯示出增加患者轉診的積極初步結果，這可能導致RNS療法更廣泛的採用。
Risks:
風險：
Despite positive trends, the growth rate for the RNS sales could be influenced by seasonal variations and market conditions.
儘管RNS銷售的增長率呈現積極趨勢，但可能會受到季節變化和市場情況的影響。
More details: NeuroPace IR
更多詳情：NeuroPace IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
